Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05681715 · ClinicalTrials.gov registry record · Phase 3
A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)
A Phase 3 study, sponsored by UCB Biopharma SRL.
- Completed
- Registry status
- Phase 3
- Development phase
- 62
- Enrollment target
NCT05681715 is a Phase 3 study that has completed, run by UCB Biopharma SRL. The registered enrollment target is 62 participants.
The verdict
NCT05681715, a Phase 3 study, has completed, sponsored by UCB Biopharma SRL.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 62 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the ability of study participants with generalized Myasthenia Gravis (gMG) to successfully self-administer rozanolixizumab after training in the self-administration technique using the syringe driver and manual push methods.
Interventions
- DRUG Rozanolixizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2023-04-17 |
| Est. Completion | 2024-04-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05681715
The ClinicalTrials.gov registry entry for NCT05681715 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rozanolixizumab is the first listed.
NCT05681715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05681715 about?
NCT05681715 is a clinical study titled "A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)". The purpose of this study is to evaluate the ability of study participants with generalized Myasthenia Gravis (gMG) to successfully self-administer rozanolixizumab after training in the self-administration technique using the syringe driver and manual push methods.
What is the current status of trial NCT05681715?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 62 participants. The study started on 2023-04-17. Estimated completion is 2024-04-23.
What interventions are being tested in trial NCT05681715?
The interventions under investigation include: Rozanolixizumab (DRUG).
Who is sponsoring clinical trial NCT05681715?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.